Acute liver failure in children

Pediatric Emergency Care

Volumn 23, Issue 2, 2007, Pages 129-135

  Cochran, Joel B ^a   Losek, Joseph D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acute liver failure; Multiple organ system

Indexed keywords

ACETYLCYSTEINE; AMPHOTERICIN B; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CEFUROXIME; FLUMAZENIL; GLUCOSE; LACTULOSE; NEOMYCIN; ORNITHINE ASPARTATE; PARACETAMOL; PROSTAGLANDIN E1;

BLOOD CLOTTING DISORDER; BRAIN DISEASE; BRAIN EDEMA; EXTRACORPOREAL CIRCULATION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; HYPERMETABOLISM; HYPOGLYCEMIA; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MEDLINE; MULTIPLE ORGAN FAILURE; PLASMAPHERESIS; PREDICTION; PROTEIN CALORIE MALNUTRITION; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; ALPROSTADIL; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER FAILURE, ACUTE; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; PLASMAPHERESIS; PROGNOSIS; RARE DISEASES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 33947124585     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e3180308f4b     Document Type: Review

References (83)

1. Trey C, Davidson C. The management of fulminant hepatic failure. In: Popper H, Schaffner F, eds. Progress in Liver Diseases, vol 111. New York, NY: Grun and Stratten; 1970:282-298.
2. Bhanduri B, Mieli-Vergani G. Fulminant hepatic failure: pediatric aspects. Semin Liver Dis. 1996;16:349-355.
3. Detre K. The NIDDK liver transplantation database. In: Terasaki P, ed. Clinical Transplants 1986. Los Angeles, CA: UCLA Tissue Typing Laboratory; 1986:29-33.
4. Goss J, Shackleton C, McDiarmid S, et al. Long-term results of pediatric liver transplantation. An analysis of 569 transplants. Ann Surg. 1998;228: 411-420.
5. Durand P, Debray D, Mandel R, et al. Acute liver failure in infancy: a 14-year experience of a pediatric liver transplantation center. J Pediatr. 2001;139:871-876.
6. Devictor D, Desplanques L, Debray D, et al. Emergency liver transplantation for fulminant liver failure in infants and children. Hepatology. 1992;16:1156-1162.
7. Hoofnagle J, Carithers R, Shapiro C, et al. Fulminant hepatic failure: summary of a workshop. Hepatology. 1995;21:240-252.
8. Russell G, Fitzgerald J, Clark J. Fulminant hepatic failure. J Pediatr. 1987;111:313-319.
9. Teran JC, McCullough AF. Nutrition in liver diseases. In: Gottschlich MM, ed. The Science and Practice of Nutrition Support. Dubuque, IA: Kendall/Hunt; 2001:539.
10. Ganony WF. Review of Medical Physiology. 15th ed. East Norwalk, CT: Appleton and Lange; 1991:653.
11. Walsh TS, Wigmore SJ, Hopton P, et al. Energy expenditure in acetaminophen-induced fulminant hepatic failure. Crit Care Med. 2000;28:649-654.
12. Krusko A, Deshpande K, Bonvino S. Liver failure, transplantation, and critical care. Crit Care Clin. 2003;19(2):155-183.
13. Schneeweiss B, Pammer J, Ratheiser K, et al. Energy metabolism in acute hepatic failure. Gastroenterology. 1993;105:1515-1521.
14. Riordan SM, Williams R. Fulminant hepatic failure. Clinic Liv Dis. 2000;4(1):25-45.
15. Pereira S, Langley P, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis. 1996;16:403-414.
16. Chuansumrit A, Chantarojanasiri P, Isarangkura S, et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2000;11(suppl 1):5101-5105.
17. Mehta R, Reilly JJ, Olson RE. Vitamin K therapy in severe liver disease. J Parenter Enteral Nutr. 1991;15:350-353.
18. Rahman T, Hodgson H. Clinical management of acute hepatic failure. Int Care Med. 2001;27:467-476.
19. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology. 1997;113:1930-1937.
20. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci. 1998;19:163-176.
21. Bernstein D. Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced Child's B and C cirrhosis. Semin Thromb Hemost. 2000;26:437-438.
22. Hoffman R, Mahajana P, Agmon P, et al. Successful use of recombinant activated Factor VII (NovoSeven) in controlling severe intra-abdominal bleeding after liver needle biopsy. Thromb Haemost. 2002;87:346-347.
23. Chuansumrit A, Treepongkaruna S, Phuapradit P. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost. 2001;85:748-749.
24. Hendricks H, Meijer K, DeWolf J, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation. 2001;71(3):402-405.
25. Kalicinski P, Kaminski A, Drewniak T, et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated Factor VII. Transplant Proc. 1999;31:378-379.
26. Rolando N, Harvey F, Brahm J, et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology. 1990;11:49-53.
27. Wyke RJ, Rajkovic IA, Eddleston AL, et al. Defective opsonization and complement deficiency in serum from patients with fulminant hepatic failure. Gut. 1980;21:643-649.
28. Munoz SJ. Difficult management problems in fulminant hepatic failure. Semin Liver Dis. 1993;13(4):395-413.
29. Rolando N, Gimson A, Wade J, et al. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant hepatic failure. Hepatology. 1993;17:196-201.
30. Larcher VF, Wyke RJ, Mowat AP, et al. Bacterial and fungal infection in children with fulminant hepatic failure: possible role of opsonisation and complement deficiency. Gut. 1982;23:1037-1043.
31. Rolando N, Clapperton M, Wade J, et al. Granulocyte colony-stimulating factor improves function of neutrophils from patients with acute liver failure. Eur J Gastroenterol Hepatol. 2000;12(10): 1135-1140.
32. Imawari H, Hughes R, Gove C, et al. Fibronectin and Kupffer cell function in fulminant hepatic failure. Dig Dis Sci. 1985;30:1028-1033.
33. Rolando N, Phillpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis. 1996;16(4):389-401.
34. Salmeron J, Tito L, Rimola A, et al. Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure. J Hepatol. 1992;14:280-285.
35. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenteol. 2001;96(7):1968-1975.
36. Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis. 1996;16(3):329-338.
37. Cordoba J, Blei AT. Treatment of hepatic encephalopathy. Am J Gastroenterol. 1997;92(9):1429-1439.
38. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337(7):473-479.
39. Albrecht J, Jones EA. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. J Neuro Sci. 1999;170:138-146.
40. Colquhoun SD, Lipkin C, Connelly CA. The pathophysiology, diagnosis, and management of acute hepatic encephalopathy. Adv Int Med. 2001;46:155-176.
41. Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol. 1999;31:771-776.
42. Richardson D, Bellamy M. Intracranial hypertension in acute liver failure. Nephrol Dial Transplant. 2002;17:23-27.
43. Ede R, Williams R. Hepatic encephalopathy and cerebral edema. Semin Liver Dis. 1986;6:107-118.
44. Gill RQ, Sterling RK. Acute liver failure. J Clin Gastroenterol. 2001; 33(3):191-198.
45. Butterworth RF. Hepatic encephalopathy and brain edema in acute hepatic failure: does glutamate play a role? Hepatology. 1997;25(4): 1032-1033.
46. Albrecht J, Dolinska. Glutamine as a pathogenic factor in hepatic encephalopathy. J Neurosci Res. 2001;65:1-5.
47. Larsen FS, Knudson GM, Hansen BA. Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure. J Hepatol. 1997;27:231-238.
48. Strauss G, Hansen BA, Kirkgaard P, et al. Liver function, cerebral blood flow autoregulation, and hepatic encephalopathy in fulminant hepatic failure. Hepatology. 1997;25:837-839.
49. Ellis A, Wendon J. Circulatory, respiratory, cerebral and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis. 1996;16:379-388.
50. Inagaki M, Shaw B, Schafer D, et al. Advantages of intracranial pressure monitoring in patients with fulminant liver failure. Gastroenterology. 1992;102:A826.
51. Singer A, Olthoff K, Kim H, et al. Role of plasmapheresis in the management of acute hepatic failure in children. Ann Surg. 2001;234:418-424.
52. Sinclair S, Greig P, Blendis L, et al. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E A preliminary report. J Clin Invest. 1989;84:1063-1069.
53. Smilkstein M, Knapp G, Kulig K, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. N Engl J Med. 1988;319: 1557-1562.
54. Vale J, Proudfoot A. Paracetamol (acetaminophen) poisoning. Lancet. 1995;346:5437-5452.
55. American Academy of Pediatrics. Committee on Drugs Acetaminophen Toxicity in Children. Pediatrics. 108;2001:1020-1024.
56. Mohler CR, Nordt SP, Williams SR, et al. Prospective evaluation of mild to moderate pediatric acetaminophen exposures. Ann Emerg Med. 2000;35:239-244.
57. Wright RO, Santucci KA. Are shorter courses of N-acetylcysteine for acetaminophen poisoning safe and efficacious? A review of the literature. Clin Pediatr Emerg Med. 2001;1:222-228.
58. Prescott L. Oral or intravenous N-acetylcysteine for acetaminophen poisoning? Ann Emerg Med. 2005;45:409-413.
59. Brush DE, Boyer EW. Intravenous N-acetylcysteine for children. Pediatr Emerg Care. 2004;20:649-650.
60. Perry HE, Shannon MW. Efficacy of oral versus intravenous N-acetylcysteine in acetaminophen overdose: results of an open-label clinical trial. J Pediatr. 1998;132:149-152.
61. Mullins ME, Schmidt RU, Jang TB. What is the rate of adverse events with intravenous versus oral N-acetylcysteine in pediatric patients? Ann Emerg Med. 2004;44:547-548.
62. Harrison P, Keays R, Bray G, et al. Improved outcome in paracetamol-induced fulminant hepatic failure following late administration of N-acetylcysteine. Lancet. 1990;335:1572-1573.
63. Ben-Ari Z, Vaknin H, Tur-Kaspa R. N-acetylcysteine in acute hepatic failure (non paracetamol-induced). Hepatogastroenterology. 2000;47: 786-789.
64. Harrison P, Wendon J, Gimson A, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N J Engl Med. 1991;324:1852-1857.
65. Bucuvalas J, Ruckman F, Krug S, et al. Effect of treatment with prostaglandin E1 and N-acetylcysteine on pediatric liver transplant recipients: a single-center study. Pediatr Transplantation. 2001;5: 274-278.
66. Malatack J, Schaid D, Urbach A, et al. Choosing a pediatric recipient for orthotopic liver transplantation. J Pediatr. 1987;111:479-489.
67. Poddar U, Thapa B, Prusad A, et al. Natural history and risk factors in fulminant hepatic failure. Arch Dis Child. 2002;87:54-56.
68. Whitington P, Balistrei W. Liver transplantation in pediatrics: indications, contraindications and pretransplant management. J Pediatr. 1991;118:169-177.
69. O'Grady J, Alexander G, Hayllar K, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97: 439-445.
70. Neuberger J. Prediction of survival for patients with fulminant hepatic failure. Hepatology. 2005;41(1):19-21.
71. Tissieres P, Debray D, Dousset B, et al. Are London and Clichy indicators of prognosis accurate in infants and children with fulminant liver failure? Pediatr Transplant. 1998;2:89.
72. Debray D, Cullufi P, Devictor D, et al. Liver failure in children with hepatitis A. Hepatology. 1997;26:1018-1022.
73. Squires RH, Sokol RJ, Schneider BL, et al. Encephalopathy at presentation predicts outcome for children with acute liver failure. Abstract Hepatology. 2002;36:167A.
74. Tissieres P, Prontera W, Chevret L, et al. The pediatric risk of mortality score in infants and children with fulminant liver failure. Pediatr Transplant. 2003;7:64-68.
75. Dhawan A, Cheeseman P, Mieli-Vergani G. Approaches to liver failure in children. Pediatr Transplant. 2004;8:584-588.
76. Sokol R. The price tag of living donor liver transplantation. J Pediatr. 2004;144(6):19.
77. Merion R, Rush S, Dykstra D, et al. Predicted lifetimes for adult and pediatric split liver versus adult whole liver transplant recipients. J Am Transplant. 2004;4:1792-1797.
78. Mc Diarmid S. Liver transplantation. The pediatric challenge. Clin Liver Dis. 2000;4:1-43.
79. Ikegami T, Shiotani S, Ninomiya M. Auxiliary partial orthotopic liver transplantation from living donors. Surgery. 2002;131:5205-5210.
80. Chen S, Hewitt W, Wantanabe F, et al. Clinical experience with a porcine hepatocyte-based liver support system. Int J Artif Organs. 1996;19:664-669.
81. Samuel D, Ichal P, Feray C, et al. Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation. 2002;73:257-264.
82. Ellis A, Hughes R, Wendon J, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology. 1996;24:1446-1451.
83. Felldin M, Friman S, Backman L, et al. Treatment with the molecular adsorbent recirculating system in patients with acute liver failure. Transplant Proc. 2003;35:822-823.